End-of-day quote
Taipei Exchange
06:00:00 2024-06-17 pm EDT
5-day change
1st Jan Change
44
TWD
+0.11%
-4.03%
+14.58%
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2020
March 22, 2021 at 02:38 pm EDT
SynCore Biotechnology Co.,Ltd announced earnings results for the full year ended December 31, 2020. For the full year, the company announced sales was TWD 13.336 million compared to TWD 12.967 million a year ago. Operating loss was TWD 395.645 million compared to TWD 416.587 million a year ago. Net loss was TWD 398.918 million compared to TWD 408.637 million a year ago. Basic loss per share from continuing operations was TWD 3.83 compared to TWD 4.54 a year ago.
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 13
CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 19
CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 09
CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-11
CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-12
CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-06
CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-06
CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
22-11-10
CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
22-08-11
CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022
22-05-11
CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2021
22-03-07
CI
SynCore Biotechnology Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
21-11-09
CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2021
21-08-10
CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021
21-05-11
CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2020
21-03-22
CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Third Quarter Ended September 30, 2020
20-11-09
CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2020
20-08-11
CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2020
20-05-12
CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2019
20-02-23
CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Third Quarter Ended September 30, 2019
19-11-10
CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2019
19-08-11
CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2019
19-05-13
CI
Syncore Biotechnology Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2018
19-02-25
CI
Syncore Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2018
18-11-11
CI
Syncore Biotechnology Co., Ltd. announced that it expects to receive TWD 324 million in funding
18-07-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
SynCore Biotechnology Co.,Ltd is a Taiwan-based company principally engaged in the research, development, production and sales of therapeutic drugs. The Company's main product is SB03 Veregen. The Company is also involved in research, development and clinical trials of the injection-type anticancer drug, SB01 and the oral anticancer drug, SB01. The Company distributes its products mainly in domestic market.
More about the company
1st Jan change
Capi.
+14.58% 47.72M +14.84% 122B +18.31% 113B +3.61% 22.66B -18.26% 21.34B -41.55% 16.92B -14.23% 16.68B -16.03% 16.61B -0.68% 13.62B +21.87% 11.04B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1